Article By:
Quad 7 Capital
Friday, March 2, 2018 8:24 PM EDT
Conatus Pharmaceuticals was initiated with Outperform rating and $16 (208% upside) price target at Oppenheimer. The stock is absolutely flying on this news, but there are other reasons to be bullish beyond today’s action.